What is new in the treatment of gynaecological cancer including ovarian cancer, cervical cancer and endometrial cancer? Read our gynaecological cancer blog and learn more about the latest advancements in the treatment female cancers.

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

Adding ipilimumab (IPI [Yervoy®, Bristol-Myers Squibb]) to nivolumab (NIVO [Opdivo®, Bristol-Myers Squibb]) induction followed by maintenance with single-agent NIVO had a superior objective tumour response rate and progression-free survival (PFS) when compared to NIVO alone in patients with persistent or recurrent epithelial ovarian cancer.

Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

 

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

 

cancer awareness improves outcome medipaper medical communications

Cancer symptom awareness linked to survival

Increased cancer awareness improves survival, according to a recent study by Cancer Research UK (CRUK) published in the British Journal of Cancer (BJC). The researchers matched cancer symptom awareness from a population-based survey in over 35,000 people across the UK with the cancer registry.

2016 ASCO ovarian cancer guidelines neo-adjuvant chemotherapy medipaper medical communications

ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated

In women with stage IIIC or IV ovarian cancer, primary cytoreductive surgery (PCS) may be preferred when there is a high chance to achieve cytoreduction to <1 cm with acceptable morbidity. This was concluded by an expert panel who published clinical guidelines in the Journal of Clinical Oncology (JCO) this week.

ASCO 2016 Palbociclib Data MediPaper Medical Communications

ASCO16 palbociclib (Ibrance©) Data

Exclusive subscriber download.